An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient.
Colon perforation
Everolimus
Polmacoxib, Nonsteroidal anti-inflammatory agents
mTOR inhibitor
Journal
Annals of coloproctology
ISSN: 2287-9714
Titre abrégé: Ann Coloproctol
Pays: Korea (South)
ID NLM: 101605121
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
05
2019
accepted:
17
08
2019
pubmed:
18
3
2020
medline:
18
3
2020
entrez:
18
3
2020
Statut:
ppublish
Résumé
Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.
Identifiants
pubmed: 32178492
pii: ac.2019.08.17
doi: 10.3393/ac.2019.08.17
pmc: PMC8134926
doi:
Types de publication
Case Reports
Langues
eng
Pagination
120-124Références
Presse Med. 2009 Sep;38(9):1370-4
pubmed: 19349140
Clin Orthop Surg. 2017 Dec;9(4):439-457
pubmed: 29201297
Am J Transplant. 2004 Sep;4(9):1549-51
pubmed: 15307846
Joint Bone Spine. 2005 Jul;72(4):286-94
pubmed: 16038840
Breast Cancer Res Treat. 2013 Aug;140(3):453-62
pubmed: 23907751
Ann Oncol. 2014 Apr;25(4):763-773
pubmed: 24667713
Transplantation. 2002 Sep 15;74(5):739-43
pubmed: 12352895
J Am Acad Dermatol. 2003 Mar;48(3):311-40
pubmed: 12637912
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Pediatr Transplant. 2005 Feb;9(1):97-100
pubmed: 15667620
Transpl Int. 2006 May;19(5):430-1
pubmed: 16623879